JP2020508327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508327A5 JP2020508327A5 JP2019546029A JP2019546029A JP2020508327A5 JP 2020508327 A5 JP2020508327 A5 JP 2020508327A5 JP 2019546029 A JP2019546029 A JP 2019546029A JP 2019546029 A JP2019546029 A JP 2019546029A JP 2020508327 A5 JP2020508327 A5 JP 2020508327A5
- Authority
- JP
- Japan
- Prior art keywords
- het
- hydrogen
- branched
- alkyl
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 101710088194 Dehydrogenase Proteins 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 1
- CDDGNGVFPQRJJM-UHFFFAOYSA-N 3-fluoropyrrolidine Chemical compound FC1CCNC1 CDDGNGVFPQRJJM-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- -1 tautomers Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741006586 | 2017-02-24 | ||
| IN201741006586 | 2017-02-24 | ||
| PCT/EP2018/054602 WO2018154088A1 (en) | 2017-02-24 | 2018-02-23 | 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508327A JP2020508327A (ja) | 2020-03-19 |
| JP2020508327A5 true JP2020508327A5 (enExample) | 2021-04-01 |
| JP7146785B2 JP7146785B2 (ja) | 2022-10-04 |
Family
ID=61563366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546029A Active JP7146785B2 (ja) | 2017-02-24 | 2018-02-23 | ジヒドロオロテートオキシゲナーゼ阻害剤としての１、４、６－トリ置換－２－アルキル－１Ｈ－ベンゾ［ｄ］イミダゾール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11028054B2 (enExample) |
| EP (1) | EP3585772B1 (enExample) |
| JP (1) | JP7146785B2 (enExample) |
| KR (1) | KR20190120786A (enExample) |
| CN (1) | CN110325514B (enExample) |
| AU (1) | AU2018223982B2 (enExample) |
| BR (1) | BR112019017567A2 (enExample) |
| CA (1) | CA3053068A1 (enExample) |
| EA (1) | EA201991916A1 (enExample) |
| IL (1) | IL268843B (enExample) |
| MA (1) | MA47593A (enExample) |
| MX (1) | MX2019010096A (enExample) |
| WO (1) | WO2018154088A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| CN113456817B (zh) * | 2020-03-30 | 2024-05-10 | 华东理工大学 | 抗rna病毒药物的dhodh抑制剂及其应用 |
| US20230227411A1 (en) * | 2020-04-16 | 2023-07-20 | Hoffmann-La Roche Inc. | Benzimidazole Derivatives |
| EP4136076A1 (en) * | 2020-04-16 | 2023-02-22 | F. Hoffmann-La Roche AG | Biphenyl derivatives |
| CN115427402A (zh) * | 2020-04-16 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 氨基磺酰胺衍生物 |
| EP4136077A1 (en) * | 2020-04-16 | 2023-02-22 | F. Hoffmann-La Roche AG | Benzimidazole derivatives |
| EP4136074A1 (en) * | 2020-04-16 | 2023-02-22 | F. Hoffmann-La Roche AG | Indazole derivatives |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| ES2102367T3 (es) | 1990-05-18 | 1997-08-01 | Hoechst Ag | Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion. |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| ATE391492T1 (de) | 1997-07-29 | 2008-04-15 | Alcon Lab Inc | Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat |
| US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
| WO1999038504A1 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| EP1237546A2 (en) * | 1999-10-01 | 2002-09-11 | Institute of Molecular and Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| DE602004023516D1 (de) | 2003-08-07 | 2009-11-19 | Allergan Inc | Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| SG174125A1 (en) * | 2009-04-02 | 2011-10-28 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| HUE042032T2 (hu) * | 2013-02-25 | 2019-06-28 | Aurigene Discovery Tech Ltd | Triszubsztituált benzotriazol-származékok, melyek dihidro-orotát-oxigenáz-inhibitor hatásúak |
-
2018
- 2018-02-23 WO PCT/EP2018/054602 patent/WO2018154088A1/en not_active Ceased
- 2018-02-23 KR KR1020197027373A patent/KR20190120786A/ko not_active Withdrawn
- 2018-02-23 EP EP18708631.9A patent/EP3585772B1/en active Active
- 2018-02-23 EA EA201991916A patent/EA201991916A1/ru unknown
- 2018-02-23 CA CA3053068A patent/CA3053068A1/en active Pending
- 2018-02-23 JP JP2019546029A patent/JP7146785B2/ja active Active
- 2018-02-23 BR BR112019017567-9A patent/BR112019017567A2/pt not_active Application Discontinuation
- 2018-02-23 MA MA047593A patent/MA47593A/fr unknown
- 2018-02-23 CN CN201880013651.0A patent/CN110325514B/zh not_active Expired - Fee Related
- 2018-02-23 MX MX2019010096A patent/MX2019010096A/es unknown
- 2018-02-23 AU AU2018223982A patent/AU2018223982B2/en not_active Ceased
- 2018-02-23 US US16/488,151 patent/US11028054B2/en not_active Expired - Fee Related
-
2019
- 2019-08-22 IL IL268843A patent/IL268843B/en unknown